A23V2200/318

Peptide exhibiting wrinkle-improving activity and uses thereof
11103436 · 2021-08-31 · ·

A peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, a pharmaceutical composition for preventing or treating skin disease including the peptide, a cosmetic composition for skin condition improvement including the peptide, a food composition for skin condition improvement including the peptide, a method of preventing or treating skin disease using the peptide, and a use of the peptide in preventing or treating skin disease or improving skin condition are described.

Peptide exhibiting wrinkle-improving activity and uses thereof
11103436 · 2021-08-31 · ·

A peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, a pharmaceutical composition for preventing or treating skin disease including the peptide, a cosmetic composition for skin condition improvement including the peptide, a food composition for skin condition improvement including the peptide, a method of preventing or treating skin disease using the peptide, and a use of the peptide in preventing or treating skin disease or improving skin condition are described.

Plant extract obtained from Morus plant leaves, compositions containing same, method of extraction and uses thereof
11090349 · 2021-08-17 · ·

An extract from leaves of mulberry is disclosed. The extract has an IC.sub.50 value sufficient to inhibit α-glucosidase I. The extract may comprise 5-40% (w/w) total imino sugars and 20-70% (w/w) total amino acids. The extract may reduce the production of melanin for the treatment of such ailments or diseases caused by pigmentation as freckle, chloasma, striae gravidarum, sensile plaque and melanoma. The extract may also control blood glucose level.

Plant extract obtained from Morus plant leaves, compositions containing same, method of extraction and uses thereof
11090349 · 2021-08-17 · ·

An extract from leaves of mulberry is disclosed. The extract has an IC.sub.50 value sufficient to inhibit α-glucosidase I. The extract may comprise 5-40% (w/w) total imino sugars and 20-70% (w/w) total amino acids. The extract may reduce the production of melanin for the treatment of such ailments or diseases caused by pigmentation as freckle, chloasma, striae gravidarum, sensile plaque and melanoma. The extract may also control blood glucose level.

Composition for use in the prevention and/or treatment of skin conditions and skin diseases

The invention discloses a composition comprising oligosaccharide, for use in the prevention and/or treatment of skin conditions and/or skin diseases by increasing SCFA, in particular colonic propionate and butyrate. Said skin disease is in particular atopic dermatitis.

Compositions for the skin

The present invention relates to a composition comprising hyaluronic acid, dermatan sulfate, at least one omega-3 fatty acid, and at least one nucleotide. It also relates to the new composition for use in the treatment or prevention of diseases, ailments, dysfunctions, or alterations of the skin, preferably atopic dermatitis. The composition may be in the form of a pharmaceutical composition, food supplement, functional food, or medical food.

COMPOSITION FOR INHIBITING IMMUNE CELL PROLIFERATION COMPRISING SIALYLLACTOSE OR DERIVATIVE THEREOF AND METHOD THEREOF
20210236525 · 2021-08-05 · ·

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG.sub.2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

COMPOSITION FOR INHIBITING IMMUNE CELL PROLIFERATION COMPRISING SIALYLLACTOSE OR DERIVATIVE THEREOF AND METHOD THEREOF
20210236525 · 2021-08-05 · ·

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG.sub.2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

IN SITU GELIFYING POWDER

The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate,—pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition.

IN SITU GELIFYING POWDER

The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate,—pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition.